PURPOSE:
Skin fibrosis and scarring can result in devastating disfigurement and permanent functional loss. Currently, there are no treatment modalities able to prevent or reverse this fibrotic process, and scars and their consequences result in an enormous medico-economic burden. Thus, it is of paramount importance to better understand the key pathogenic mechanisms driving this pathological fibrotic process. We recently described a mouse model in which overexpression of JUN, an AP-1 transcription factor, can be induced to produce global tissue fibrosis. Here, we explored the effects of JUN overexpression in skin scarring and fibrosis and the ability of our mouse to model hypertrophic scarring and excessive skin fibrosis in response to wounding.
METHODS:
Stented excisional dorsal wounds were created in transgenic JUN (c-Jun tetO R26-M2rtTA) and Rosa (Rosa26-rtTA) control mice. Doxycycline (2mg/ml) was used to induce JUN overexpression in the wound beds on the day of surgery (POD 0) and every other day until the wounds healed (postoperative day 14, POD 14). On alternate days throughout the healing response, wounds were harvested and analyzed histologically for thickness and collagen deposition, and by fluorescent activated cell sorting (FACS) to compare the relative percentages of fibroblast subpopulations. To study the role of JUN in human scars, dermal fibroblasts were isolated from hypertrophic scars (HTS) and healthy control skin (NS) and transduced to knock out JUN using a CRISPR-Cas 9 method. Proliferation and apoptosis were compared in the knock-out (KO) and non-KO human dermal fibroblasts.
RESULTS:
The wounds of JUN mice healed at a significantly accelerated rate between POD5 and POD14 (*p<0.05). Compared to the wounds of Rosa control mice, the scars of JUN mice on POD14 were significantly thicker, and although collagen content was not different, it was more disordered on Hematoxylin and Eosin staining, and brighter and more branched upon computational assessment of Picrosirius stained wounds (*p<0.05). JUN overexpression resulted in a significant expansion of reticular fibroblasts at the expense of lipofibroblasts, evident on POD 7 (*p<0.05). Translating these results to human scars; JUN CRISPR-Cas 9 deletion increased apoptosis and decreased proliferation of primary cultures of HTS and NS fibroblasts.
CONCLUSION: JUN overexpression increases the fibrotic cutaneous wound healing response by significantly expanding reticular dermal fibroblasts at the expense of the dermal lipofibroblasts. In addition, assessment of HTS and NS fibroblasts isolated from human skin indicate that JUN also mediates the fibrotic response in human disease by inhibiting apoptosis and driving proliferation of the dermal fibroblast subsets. Thus, our novel inducible JUN mouse model can be used to explore the mechanisms driving HTS and other pathological skin fibrosis and facilitate targeted identification of new treatments.
Altered Iron-Mediator Expression Identifies Chemotherapeutic Effects of Deferoxamine on Head and Neck Squamous Cell Carcinoma

PSRC Abstract Supplement
University of Michigan, Ann Arbor, MI, USA PURPOSE: We have previously validated the pre-clinical use of deferoxamine (DFO) as an osteogenic stimulant capable of preventing non-unions in irradiated mandible fractures. DFO indirectly bolsters bone formation by stimulating angiogenesis and restoring diminished vascularity within irradiated tissues. Despite this promise, there have been concerns regarding the use of DFO to treat osseous defects in head and neck cancer survivors due to its remarkable ability to induce angiogenesis and promote tissue vascularization. Because of its iron chelating mechanism of action, we subsequently demonstrated that DFO actually elicits toxic, anti-tumorigenic actions on MDA-1986 head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo. Aside from iron's critical metabolic functions, it is also crucial for the survival of rapidly dividing cancer cells, and its removal intensely inhibits tumor formation. In essence, DFO kills cancer cells by depleting iron stores that these rapidly dividing cells require, while protecting angiogenic mechanisms and stimulating the normal growth of blood vessels in injured tissues.
To further investigate this line of inquiry, we surveyed the Alabama HNSCC patient survivorship TGCA database for iron related genes and found that Transferrin Receptor Protein (TFRC) and Ferritin Heavy Chain-1 (FTH-1) were significantly upregulated in HNSCC, suggesting that dysregulation of iron mediators play a role in HNSCC development. Based on these observations, we posited that DFO exposure would alter HNSCC iron-mediator expression.
METHODS:
We analyzed human MDA-1986 and UMSCC 108 HNSCC cells (HPV + and -cells, respectively) with and without DFO treatment (50 and 100µM) with Western Blot analysis for TFRC and FTH-1. DFO treated cells were also compared to non-treated controls and positive controls (5Gy radiation [XRT] ). All experiments were conducted in triplicate. Subsequently, we developed in vivo tagged buccal xenografts in Nu/Nu mice. Mice were randomly assigned to control, XRT, and DFO groups (n=5/group). XRT mice received 3 fractionated doses of 3 Gy over 10 days. DFO mice received 5 peritumoral injections of DFO (100µM each). Tumor volumes were measured every third day (ANOVA, p ≥ 0.05). After 12 weeks, excised tumors were analyzed with western blot and qPCR.
RESULTS:
In vitro we found that both cell lines downregulated TFRC in response to 100µM DFO, FTH-1 was downregulated in HPV-cells, but was decreased throughout all groups in HPV+ cells (untreated and treated). In vivo, we observed a significant decrease in tumor volume upon addition of DFO and downregulation of FTH-1 was observed and validated with western blot and qPCR in DFO treated tumors.
CONCLUSION:
These results suggest that DFO is not only safe to use in HNSCC, but it may offer a promising chemotherapeutic approach for oncologic management. Additionally, its chemotherapeutic properties can be gauged utilizing unique signature gene patterns of iron mediator expression as biomarkers within varying subtypes of HNSCC. Due to the heterogeneous nature of HNSCC, further studies examining the effects of DFO in a variety of HNSCC subtypes are warranted. 
METHODS:
Inclusion criteria for this study were MFT harvest for scaphoid or lunate reconstruction by a single surgeon between 2012 and 2017, and post-operative followup exceeding 6 months. Medical records were reviewed for patient (sex, age, BMI) and operative details. Knee range of motion (ROM) was measured using a handheld goniometer. PROs used to assess the knee include IKDC (International Knee Documentation Committee), AKPS (Anterior Knee Pain Scale), KOOS (Knee Injury and Osteoarthritis Outcomes Score) and WOMAC (Western Ontario McMaster Universities Osteoarthritis Index). Patients were asked to return for a physical exam of the knee and to complete patient reported outcomes questionnaires (PROs). For patients unable to come for a physical exam, PROs were offered electronically. Pre-and post-operative data were compared using t-tests to quantify donor site morbidity.
